Michael Holder's most recent trade in Cytek BioSciences Inc was a trade of 43,973 Restricted Stock Units done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytek BioSciences Inc | Michael Holder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 43,973 | 43,973 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Michael Holder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 23,809 | 23,809 | - | - | Director Stock Option (right to buy) | |
| Cytek BioSciences Inc | Michael Holder | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 1,454 | 7,997 | - | - | Common Stock | |
| Cytek BioSciences Inc | Michael Holder | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 1,454 | 18,181 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Michael Holder | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,908 | 6,543 | - | - | Common Stock | |
| Cytek BioSciences Inc | Michael Holder | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,908 | 19,635 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Michael Holder | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 2,181 | 3,635 | - | - | Common Stock | |
| Cytek BioSciences Inc | Michael Holder | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 2,181 | 22,543 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Michael Holder | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 1,454 | 24,724 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Michael Holder | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 1,454 | 1,454 | - | - | Common Stock | |
| Cytek BioSciences Inc | Michael Holder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 37,878 | 37,878 | - | - | Stock Option (right to buy) | |
| Cytek BioSciences Inc | Michael Holder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,178 | 26,178 | - | - | Restricted Stock Units | |
| AVITA Medical Inc | Michael Holder | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 35,950 | 46,450 | - | - | Common Stock | |
| AVITA Medical Inc | Michael Holder | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 20,650 | 20,650 | - | - | Stock Options (Right to Buy) | |
| AVITA Medical Inc | Michael Holder | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2021 | 10,500 | 10,500 | - | - | Common Stock | |
| AVITA Medical Inc | Michael Holder | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2021 | 6,925 | 6,925 | - | - | Stock Options (Right to Buy) | |
| AVITA Medical Inc | Michael Holder | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 112,500 | 112,500 | - | - | Stock Options (Right to Buy) | |
| AVITA Medical Inc | Michael Holder | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2021 | 37,500 | 37,500 | - | - | Stock Options (Right to Buy) |